In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation.

ABSTRACT: Antibodies isolated from human donors are increasingly being developed for anti-infective therapeutics. These antibodies undergo affinity maturation in vivo, minimizing the need for engineering of therapeutic leads for affinity. However, the affinities required for some therapeutic applications may be higher than the affinities of the leads obtained, requiring further affinity maturation in vitro. To improve the neutralization potency of natural human antibody MSL-109 targeting human cytomegalovirus (CMV), we affinity matured the antibody against the gH/gL glycoprotein complex. A phage display library where most of the six complementary-determining regions (CDRs) were allowed to vary in only one amino acid residue at a time was used to scan for mutations that improve binding affinity. A T5

SUBMITTER: Li B 

PROVIDER: S-EPMC3984332 | biostudies-literature | 2014 Mar-Apr

REPOSITORIES: biostudies-literature